Aptimmune Biologics Adds CEO and Technical Consultant to Management Team
with No Comments

  St. Louis, MO (January 8, 2019) – Aptimmune Biologics announces the addition of two members to the company’s management team to start the New Year. Heather Bessoff, DVM, has joined the company as chief executive officer. In her new … Read More

Aptimmune Biologics and Kemin Industries Announce Partnership
with No Comments

Kemin Industries acquires equity position in Aptimmune Biologics and creates Kemin Biologics to market Aptimmune’s Barricade™ technology in swine  DES MOINES, IA/ST. LOUIS, MO (August 7, 2018) – Today Aptimmune Biologics and Kemin Industries officially announced their partnership in the … Read More

Aptimmune Completes $6 Million Series B Funding, Moves Headquarters & Lab to St. Louis
with No Comments

St. Louis, Mo. (January 22, 2018) – Aptimmune Biologics announces it has completed its Series B funding initiative, raising more than $6 million from several investors. This increases the combined total investment to almost $9 million, generated by the company … Read More

Aptimmune Biologics Receives Iowa Biotech Innovation Showcase’s Top Company Award
with No Comments

Swine-vaccine developer recognized as Top Company at this year’s Partnering for Growth Biotech Innovation Showcase & Forum  CHAMPAIGN, Illinois (March 24, 2017) – Aptimmune Biologics was awarded this year’s Biotech Innovation Showcase’s Top Company Award at the 2017 Partnering for … Read More

Iowa State University and Aptimmune Join Forces to Improve PRRSV Isolation
with No Comments

CHAMPAIGN, Ill. (December 14, 2016) – The Iowa State University Veterinary Diagnostic Laboratory is teaming up with Aptimmune Biologics Inc. to develop innovative solutions to fight costly viral diseases of swine. The agreement enables Iowa State to use Aptimmune’s patented … Read More

Aptimmune Biologics Selected by The Yield Lab to Participate in Ag Technology Accelerator Program
with No Comments

Swine mucosal vaccine company received $100,000 in funding, plus networking, mentorship and other support CHAMPAIGN, Illinois (November 17, 2016) – Aptimmune Biologics was selected by The Yield Lab, a St. Louis-based agriculture technology business accelerator and investor, to participate in a … Read More

Aptimmune Uses Novel Technology to Fight Swine Pathogens
with No Comments

JAMIE JOHANSEN | AgWired | June 21, 2016 Just last year the small team raised their first round of funding and brought on CEO, Aaron Gilbertie, to help lead the company through the development, product registration and commercialization of Aptimmune’s … Read More

Aptimmune Offering New Vaccination Technology
with No Comments

SwineCast | July 12, 2016 Aptimmune Biologics is bringing new intra-nasal vaccination technology to the swine industry.  CEO Aaron Gilbertie discusses the company’s focus and products at World Pork Expo. Read More…

Swine Vaccine Maker at Ag Innovations Showcase
with No Comments

JULIE HARKER | Brownfield Ag News | September 21, 2016 A wide variety of ag innovators is asking for support at the Ag Innovations Showcase. A startup company that provides crickets for poultry feed, a tropical weather forecast provider for … Read More

Aptimmune Biologics Raises $2.75 Million of Series A Funding Led by Arsenal Capital Management
with No Comments

Company will create new swine vaccines based on advanced mucosal technology New CEO joins the company to drive development and commercialization CHAMPAIGN, Illinois – July 7, 2015 – Aptimmune Biologics, a mucosal vaccine company developing novel swine vaccines for PRRSV … Read More